Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'
You may also be interested in...
Pharmacy benefit manager Express Scripts plans to shake up the asthma/pulmonary and multiple sclerosis categories in 2018 with new contracting programs.
Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.
US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.